54 related articles for article (PubMed ID: 14506181)
21. A novel one-armed anti-c-Met antibody inhibits glioblastoma growth in vivo.
Martens T; Schmidt NO; Eckerich C; Fillbrandt R; Merchant M; Schwall R; Westphal M; Lamszus K
Clin Cancer Res; 2006 Oct; 12(20 Pt 1):6144-52. PubMed ID: 17062691
[TBL] [Abstract][Full Text] [Related]
22. Cytotoxicity against human tumor cells mediated by the conjugate of anti-epidermal growth factor receptor monoclonal antibody to recombinant ricin A chain.
Masui H; Kamrath H; Apell G; Houston LL; Mendelsohn J
Cancer Res; 1989 Jul; 49(13):3482-8. PubMed ID: 2786451
[TBL] [Abstract][Full Text] [Related]
23. Regional and systemic distribution of anti-tumor x anti-CD3 heteroaggregate antibodies and cultured human peripheral blood lymphocytes in a human colon cancer xenograft.
Nelson H; Ramsey PS; Kerr LA; McKean DJ; Donohue JH
J Immunol; 1990 Nov; 145(10):3507-15. PubMed ID: 1700013
[TBL] [Abstract][Full Text] [Related]
24. Radiolocalization of xenografted human malignant melanoma by a monoclonal antibody (9.2.27) to a melanoma-associated antigen in nude mice.
Hwang KM; Fodstad O; Oldham RK; Morgan AC
Cancer Res; 1985 Sep; 45(9):4150-5. PubMed ID: 4028007
[TBL] [Abstract][Full Text] [Related]
25. 211At radioimmunotherapy of subcutaneous human ovarian cancer xenografts: evaluation of relative biologic effectiveness of an alpha-emitter in vivo.
Bäck T; Andersson H; Divgi CR; Hultborn R; Jensen H; Lindegren S; Palm S; Jacobsson L
J Nucl Med; 2005 Dec; 46(12):2061-7. PubMed ID: 16330571
[TBL] [Abstract][Full Text] [Related]
26. Deletion of the ectodomain unleashes the transforming, invasive, and tumorigenic potential of the MET oncogene.
Merlin S; Pietronave S; Locarno D; Valente G; Follenzi A; Prat M
Cancer Sci; 2009 Apr; 100(4):633-8. PubMed ID: 19175607
[TBL] [Abstract][Full Text] [Related]
27. c-Met ectodomain shedding rate correlates with malignant potential.
Athauda G; Giubellino A; Coleman JA; Horak C; Steeg PS; Lee MJ; Trepel J; Wimberly J; Sun J; Coxon A; Burgess TL; Bottaro DP
Clin Cancer Res; 2006 Jul; 12(14 Pt 1):4154-62. PubMed ID: 16857786
[TBL] [Abstract][Full Text] [Related]
28. c-erbB2 protein overexpression in breast cancer as a target for PET using iodine-124-labeled monoclonal antibodies.
Bakir MA; Eccles S; Babich JW; Aftab N; Styles J; Dean CJ; Lambrecht RM; Ott RJ
J Nucl Med; 1992 Dec; 33(12):2154-60. PubMed ID: 1460508
[TBL] [Abstract][Full Text] [Related]
29. Radio-immunotargeting in experimental animal models of intraperitoneal cancer.
Fjeld JG; Vergote I; De Vos L; Nustad K
Acta Obstet Gynecol Scand Suppl; 1992; 155():105-11. PubMed ID: 1502887
[TBL] [Abstract][Full Text] [Related]
30. Variables influencing cell binding assays for antibody binding kinetics.
Boonkitticharoen V; Laohathai K
Nucl Med Commun; 1993 Jan; 14(1):70-5. PubMed ID: 8423938
[TBL] [Abstract][Full Text] [Related]
31. Patient-Derived Tumor Xenografts: Why Now?
Liu ET; Bult CJ; Shultz LD
JAMA Oncol; 2016 May; 2(5):567-568. PubMed ID: 27055176
[No Abstract] [Full Text] [Related]
32. Recent progress in the imaging of c-Met aberrant cancers with positron emission tomography.
Floresta G; Abbate V
Med Res Rev; 2022 Jul; 42(4):1588-1606. PubMed ID: 35292998
[TBL] [Abstract][Full Text] [Related]
33. Imaging c-Met expression using 18F-labeled binding peptide in human cancer xenografts.
Li W; Zheng H; Xu J; Cao S; Xu X; Xiao P
PLoS One; 2018; 13(6):e0199024. PubMed ID: 29894497
[TBL] [Abstract][Full Text] [Related]
34. Analysis of progress and challenges for various patterns of c-MET-targeted molecular imaging: a systematic review.
Han Z; Wu Y; Wang K; Xiao Y; Cheng Z; Sun X; Shen B
EJNMMI Res; 2017 Dec; 7(1):41. PubMed ID: 28485003
[TBL] [Abstract][Full Text] [Related]
35. Design and Feasibility Study of a Single Photon Emission Microscope System for Small Animal I-125 Imaging.
Meng LJ; Clinthorne NH; Skinner S; Hay RV; Gross M
IEEE Trans Nucl Sci; 2006 Jun; 53(3):1168-1178. PubMed ID: 28255179
[TBL] [Abstract][Full Text] [Related]
36. Theranostic applications of antibodies in oncology.
Fleuren ED; Versleijen-Jonkers YM; Heskamp S; van Herpen CM; Oyen WJ; van der Graaf WT; Boerman OC
Mol Oncol; 2014 Jun; 8(4):799-812. PubMed ID: 24725480
[TBL] [Abstract][Full Text] [Related]
37. A novel multipurpose monoclonal antibody for evaluating human c-Met expression in preclinical and clinical settings.
Knudsen BS; Zhao P; Resau J; Cottingham S; Gherardi E; Xu E; Berghuis B; Daugherty J; Grabinski T; Toro J; Giambernardi T; Skinner RS; Gross M; Hudson E; Kort E; Lengyel E; Ventura A; West RA; Xie Q; Hay R; Vande Woude G; Cao B
Appl Immunohistochem Mol Morphol; 2009 Jan; 17(1):57-67. PubMed ID: 18815565
[TBL] [Abstract][Full Text] [Related]
38. Construction of human naïve Fab library and characterization of anti-met Fab fragment generated from the library.
Jiao Y; Zhao P; Zhu J; Grabinski T; Feng Z; Guan X; Skinner RS; Gross MD; Hay RV; Tachibana H; Cao B
Mol Biotechnol; 2005 Sep; 31(1):41-54. PubMed ID: 16118414
[TBL] [Abstract][Full Text] [Related]
39. Radioimmunoscintigraphy of human met-expressing tumor xenografts using met3, a new monoclonal antibody.
Hay RV; Cao B; Skinner RS; Wang LM; Su Y; Resau JH; Knudsen BS; Gustafson MF; Koo HM; Vande Woude GF; Gross MD
Clin Cancer Res; 2003 Sep; 9(10 Pt 2):3839S-44S. PubMed ID: 14506181
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
